碩士 / 臺北醫學大學 / 醫學檢驗暨生物技術學系所 / 102 / Alzheimer’s disease (AD) is a progressive neurodegenerative disease. Its diagnosis largely depends on the experience of clinical staff. It is not helpful for an early treatment of AD. Therefore we wanted to find out biomarkers which show a significant difference in patient’s serum to help on disease diagnosis, tracking and treatment. Recent studies have shown that neurodegenerative Huntington’s disease (HD) associated protein 1(HAP1) is related in the trafficking of AD protein, amyloid precursor protein (APP). This study is to analyze Hap1-related protein concentrations in AD patients’ serum comparing to normal individuals’. Therefore, we collected serum samples from AD patients and normal controls’. Analysis of the clinical characteristics of the subjects revealed that there are no significant differences. It’s not easily to separate patient and normal by Blood biochemical test. Using Western blot analysis, we found that the concentrations of Abelson helper integration site-1(AHI-1 or Jouberin), dynein 1 light intermediate chain 2 (DYNC1LI2; Dynein) and Kinesin light chain 2 (KLC2) have significantly decreased in AD serum. Enzyme-linked immunosorbent assay (ELISA) gave us consistent results. In the future, we will establish a cell model to test the results from the serum analysis, and understand the influence of these proteins to cells by overexpression or knockdown.
Identifer | oai:union.ndltd.org:TW/102TMC05108016 |
Date | January 2014 |
Creators | Li-Yu Yang, 楊力宇 |
Contributors | 林詠峯 |
Source Sets | National Digital Library of Theses and Dissertations in Taiwan |
Language | zh-TW |
Detected Language | English |
Type | 學位論文 ; thesis |
Format | 42 |
Page generated in 0.0097 seconds